SEC Comment Letter for BioNTech SE (BNTX) (CIK 0001776985) (BNTX) — Feb 25, 2020
BioNTech SE (BNTX) (CIK 0001776985)
Date: Feb. 25, 2020 · CIK: 0001776985 · Accession: 0000000000-20-001683
AI Filing Summary & Sentiment
Reasoning
Letter
February 24, 2020 Ugur Sahin, M.D. Chief Executive Officer BioNTech SE An der Goldgrube 12 D-55131 Mainz Germany Re:BioNTech SE Draft Registration Statement on Form F-4 Filed February 20, 2020 CIK No. 0001776985 Dear Dr. Sahin: This is to advise you that we do not intend to review your registration statement. We request that you publicly file your registration statement no later than 48 hours prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Paul Fischer at 202-551-3415 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Eric Blanchard, Esq.
Show Raw Text
February 24, 2020
Ugur Sahin, M.D.
Chief Executive Officer
BioNTech SE
An der Goldgrube 12
D-55131 Mainz
Germany
Re:BioNTech SE
Draft Registration Statement on Form F-4
Filed February 20, 2020
CIK No. 0001776985
Dear Dr. Sahin:
This is to advise you that we do not intend to review your registration statement.
We request that you publicly file your registration statement no later than 48 hours prior
to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you that the company and its management are responsible for the
accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or
absence of action by the staff.
Please contact Paul Fischer at 202-551-3415 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Eric Blanchard, Esq.